Akebia Therapeutics | AKBA - 股票



金融业
股票价格
USD
资产
USD 362.52M
现金及等价物
USD 162.64M
销售成本
USD 10.34M
流动资产
USD 243.48M
流动负债
USD 173.88M
债务
USD 46.51M
股息收益率
0
EBIT
USD -5.45M
EBITDA
USD 14.03M
员工
167
EPS每股收益
USD -0.04
股本和储备
USD 27.38M
销售毛利
USD 47.28M
债务利息支出
362.52M
贷款资金
USD 36.4M
市值
USD 274.3M
净收入
USD -12.24M
营业费用
USD 63.08M
营业利润
USD -5.45M
普通股股本
USD 265.43M
PE价格收益
1.63K
税前利润
USD -11.24M
销售收入
USD 57.62M
销售和管理费用
USD 23.53M
股票
USD 13M
贸易债权人
USD 8.39M
应收帐款人
USD 47.03M


股票 更改 日
Acadia Pharmaceuticals USD 31.57M 3.1M 2026-03
Agios Pharmaceuticals USD 35.75M 665K 2026-06
Akebia Therapeutics USD 13M 2.61M 2026-03
Alnylam Pharmaceuticals USD 97.11M 103.04M 2026-06
Amgen USD 6.19B 39M 2026-03
Ardelyx USD 128.02M 110.29M 2026-03
Astellas Pharma JPY 297.26B 9.92B 2025-03
AstraZeneca USD 6.93B 362M 2026-06
Bayer EUR 12.34B 3M 2025-12
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Celltrion KRW 126B 3.06B 2026-03
Cspc Pharmaceutical CNY 3.09B 219.95M 2025-12
Exelixis USD 26.6M 4.92M 2026-03
Fresenius Medical Care EUR 2.3B 162.24M 2026-03
GlaxoSmithKline GBP 6.16B 233M 2026-03
Ionis Pharmaceuticals USD 50.83M 45.28M 2026-06
J&J USD 15.14B 561M 2026-06
Kangmei Pharma CNY 2.38B 73.9M 2026-03
Karyopharm Therapeutics USD 4.04M 72K 2025-12
Knight Therapeutics CAD 95.4M 2.91M 2024-03
Laboratorios Farma EUR 327.67M 2.28M 2025-06
Lexicon Pharmaceuticals USD 276K 5K 2026-03
Medical Developments International AUD 9.45M 679K 2025-06
Moderna USD 280M 134M 2026-06
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Organigram Holdings CAD 135.16M 2.45M 2026-03
Pharma Mar EUR 53.12M 2.48M 2026-03
PTC Therapeutics USD 91.35M 15.79M 2026-06
Qiagen NV USD 309.61M 7.72M 2026-03
Regeneron Pharmaceuticals USD 3.08B 19.3M 2026-06
Roche Holding CHF 7.6B 9M 2025-06
Sanofi EUR 24.12B 620M 2026-06
Sarepta Therapeutics USD 1B 86.37M 2026-03
Sartorius EUR 831.9M 4.8M 2026-06
Sino Biopharmaceutical CNY 1.84B 156.17M 2024-06
Tilray USD 282.79M 11.9M 2025-06
Vanda Pharmaceuticals USD 1.85M 190K 2025-12
Zealand Pharma A/S 10.7M 9.9M 2024-12
Zz Pientze Pharmaceu CNY 6.28B 553.86M 2026-03